Denmark included, for example, numbers for Denmark, Greenland and the Faroe Islands, whereas the Netherlands included numbers for Curacao, Aruba and the Dutch part of Saint Martin. Causing the body to make extra IL-12 could potentially enhance the immune system’s ability to make antibodies to the spike protein. The total number of cases and deaths registered country-wise is updated regularly. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.For more details, see How the Oxford-AstraZeneca Vaccine Works.Updated Jan. 19, PHASE 3 Type: Muscle injection The New York Times reported in December that the administration passed up the chance over the summer to secure another 100 million doses. One week ago, the toll was 16,118. One week ago, the toll was 16,118. On Dec. 14, the president of the university said that the Phase 1 trial was complete and that Phase 2 would begin by the end of the month.Updated Dec. 31, PHASE 1 That discovery was enough to cause the Australian government to scrap the trial. It’s currently the only Western company to be using this traditional method, which is also being pursued in China and India. Type: Nasal spray That would make the country the first European nation to use a Chinese vaccine.In China, meanwhile, the government gave Sinopharm emergency approval over the summer to inject its vaccine candidates into government officials, health care workers, and other select groups. Other genetic vaccines in active preclinical development include vaccines from: Applied DNA Sciences, EvviVax and Takis Biotech; DIOSynVax; Elixirgen Therapeutics; ETheRNA; Globe Biotech; Greenlight Biosciences; Infectious Disease Research Institute and Amyris; Mediphage Bioceuticals; National institute of Chemistry of Slovenia and Kemijski Inštitut; National Research Centre, Egypt; the OPENCORONA Consortia; Providence Therapeutics; Scancell; the Spanish National Center for Biotechnology and the Spanish National Research Council; Vaccibody.Updated Jan. 14. Storage: Over a year at room temperature The commission claimed to have tested the vaccine on animals, but provided no data. The Finlay Vaccine Institute in Havana began testing a vaccine called Soberana 1. Brazil's deaths have more than doubled in two weeks from 11,123 to 22,716 in sixth place, according to Worldometers.info. It finally launched on Dec. 28.In September, Novavax reached an agreement with the Serum Institute of India, a major vaccine manufacturer, that could enable them to produce as many as 2 billion doses a year. Within a week, the trials began in all countries except the United States. If spike proteins are not anchored to a coronavirus, they can unfold. The researchers decorated these shells with part of the coronavirus spike protein. Efficacy: 91.4% January 20, 2021. The Phase 2 trial, which is recruiting up to 1,000 volunteers, started on Jan. 5. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response. Known as COVIran Barekat, it entered a Phase 1 trial at the end of December. By combining them, the Russian researchers hoped to avoid a situation in which the immune system could learn to recognize the vaccine as a foreign object that needed to be destroyed.The researchers launched clinical trials in June. Covid-19 Response Fund Donate In Brazil , from Jan 3 to 4:35pm CET, 17 January 2021 , there have been 8,393,492 confirmed cases of COVID-19 with 208,246 deaths . Tests on animals showed that it protected them against infection. The virus, which causes the respiratory infection Covid-19, was first detected in the city of Wuhan, China, in late 2019. In December they launched a Phase 1/2 trial with 345 participants.Updated Dec. 17, PHASE 1 To further stimulate the immune system, the company is testing so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Vaccine name: Ad26.COV2.S and over 1 Mio. Approved in Saudi Arabia and other countries. On Oct. 25, the Israeli government announced that the vaccine, called Brilife, would be going into a Phase 1 trial. On Sept. 18 Sanofi closed another deal with the European Union for 300 million doses for an unspecified amount, and later reached an agreement with Canada for up to 72 million doses. Earlier this year, they engineered the vaccine to produce part of the coronavirus spike protein as well. It would become Sanofi’s second Covid-19 vaccine candidate in clinical trials, along with their protein-based vaccine.Updated Dec. 24, PRECLINICAL The company, which is also manufacturing AstraZeneca, has been dogged by reports of corruption and scandals.Updated Dec. 9, PHASE 1 On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. In July the U.S. government awarded Novavax another $1.6 billion to support the vaccine’s clinical trials and manufacturing.After getting promising results from preliminary studies in monkeys and humans, Novavax launched a Phase 2 trial on 2,900 people in South Africa in August, and the next month it launched a Phase 3 trial with up to 15,000 volunteers in the United Kingdom. So the researchers made a small change to the protein, creating a little clamp at one end to hold the molecule in its proper shape. In the spring, researchers at the University of Tübingen in Germany created a vaccine made of eight parts of two viral proteins, along with an immune-stimulating adjuvant. When placed on the skin, the needles dissolve and deliver virus proteins into the body. Efficacy: Unknown APPROVAL: Regulators review the complete trial results and plans for a vaccine’s manufacturing, and decide whether to give it full approval. The company found that the vaccine protects monkeys from the coronavirus. The company is aiming for production of a billion doses in 2021.On Nov. 16, Johnson & Johnson announced that they were also launching a second Phase 3 trial to observe the effects of two doses of their vaccine, instead of just one.For more details, see How the Johnson & Johnson Vaccine Works.Updated Jan. 14, PHASE 2 A second plant-based vaccine is in development at Kentucky BioProcessing, an American subsidiary of British American Tobacco, the maker of Lucky Strike and other cigarettes. In September they launched a Phase 1 trial.Updated Sept. 15, PHASE 1 Accessed January 20, 2021. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/, Statista. This article provides a general overview and documents the status of locations affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes coronavirus disease 2019 (COVID-19) and is responsible for the COVID-19 pandemic.The first human cases of COVID-19 were identified in Wuhan, the capital of the province of Hubei in China in December 2019. While AstraZeneca did not comment, the Brazil trial was not paused, suggesting that the volunteer received a placebo. For more details, see How Moderna’s Vaccine Works.Updated Jan. 19, PHASE 3 Clover’s formula looks to be especially durable; the vaccine can sit out at room temperature for a month and remain viable.Clover launched a Phase 1 trial in June, and in December they announced that the vaccine triggered a high level of antibodies. On Dec. 19, Kazinform reported that Phase 2 had been completed, showing that the vaccine was safe and produced a promising immune response. World Health Organization Coronavirus disease situation dashboard presents official daily counts of COVID-19 cases and deaths worldwide, while providing a hub to other resources. When they gave the vaccine to monkeys, they found that it protected the animals from the disease. Investments from the Coalition for Epidemic Preparedness will support the development of manufacturing that could lead to the production of a billion doses a year. It contains an adenovirus called Ad5 (the same viral vector in CanSinoBio’s vaccine and in Russia’s Sputnik V).When Vaxart gave the pill to mice, they produced antibodies against the coronavirus. Efficacy: Unknown authorized the restart of the U.S. trial.On Nov. 19, researchers published the first findings from the Phase 2/3 trials in the United Kingdom. According to newspaper reports, the EpiVacCorona trials had already begun by then. The development cycle of a vaccine, from lab to clinic. The coronavirus pandemic has sickened more than 95,114,300 people, according to official counts. Unfortunately, the clamp is similar to a protein on HIV, which can lead the immune system to make HIV-like antibodies. The researchers estimated that the vaccine had an efficacy rate of 94.1 percent, far higher than experts had expected when vaccine testing began. It contains the RBD part of the coronavirus spike protein, which is fused to a standard tetanus vaccine to make it stable. See the map, stats, and news for areas affected by COVID-19 on Google News They have now used it to make a nasal spray vaccine for Covid-19, delivering the Ad5 adenovirus to the airway. On Jan. 3 the Indian government gave Zydus Cadila permission to advance to a Phase 3 trial with 30,000 volunteers. The vaccine developers did not detect any severe side effects in the trial, while observing that the vaccine raised antibodies against the coronavirus as well as other immune defenses. On Dec. 29, Biological E and the Coalition for Epidemic Preparedness Innovations announced a partnership to advance the development and manufacturing of the vaccine, with CEPI initially contributing $5 million to the effort. Researchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, created an inactivated coronavirus vaccine. Storage: 30 days with refrigeration, 6 months at –4°F (–20°C) Type: Muscle injection Efficacy: 62% to 90%, depending on dosage Track COVID-19 local and global coronavirus cases with active, recoveries and death rate on the map, with daily news and video. LIMITED USE IN CHINA Please log in to access our additional functions, *Duration: 12 months, billed annually, single license, The ideal entry-level account for individual users. Moderna has made similar deals with other countries including Canada, Japan, Qatar and South Korea. Live statistics and coronavirus news tracking the number of confirmed cases, recovered patients, tests, and death toll due to the COVID-19 coronavirus from Wuhan, China. The Vaccine and Infectious Disease Organization at the University of Saskatchewan has developed a vaccine candidate which uses protein subunits to develop immunity against the coronavirus. Researchers at Thailand’s Chulalongkorn University have been developing several potential vaccines for the coronavirus. GSK supplemented these proteins with adjuvants that stimulate the immune system. Overview and forecasts on trending topics, Key figures and rankings about brands and companies, Consumer insights and preferences in various industries, Detailed information about political and social topics, All key figures about regions and countries, Everything you need to know about Consumer Goods, Identify market potentials of the digital future, Technology Market Outlook This feature is limited to our corporate solutions. Pfizer and BioNTech will deliver an initial shipment of 2.9 million doses to the United States in the first week after Comirnaty authorization.A growing number of countries have also given emergency authorization for Comirnaty, including Argentina, Canada, Chile, Costa Rica, Ecuador, Jordan, Kuwait, Mexico, Panama, and Singapore. Did we miss something? Vaccine developers are looking to launch phase 3 studies in the U.S., Brazil, India and other countries where the COVID-19 pandemic is still raging. the first to put a Covid-19 vaccine into human trials, the effects of two doses of their vaccine, Investments from the Coalition for Epidemic Preparedness, with the European Union for 300 million doses, the first coronavirus vaccine created in India, to develop Covaxin for the United States market, Frequently Asked Questions About the Covid Data. Coronavirus: Brazil is third worst-hit country - but its regions could ease lockdown. Efficacy: Unknown Updated Statistics, graphs, and data tables showing the total number of cases, cases per day, cases by country, cases outside of Hubei in China, recoveries and discharges, newly infected, active cases, outcome of closed cases: death rate vs. recovery rate for patients infected with the COVID-19 Coronavirus originating from Wuhan, China Vaccines already in use for other diseases that may also protect against Covid-19. Dose: 2 doses, 3 weeks apart They launched Phase 2 trials in July, followed by a Phase 3 trial with 29,000 volunteers in December.Updated Dec. 2, PHASE 2 PHASE 3 COMBINED PHASES Later that month, Pfizer and BioNTech reached an agreement to supply 100 million doses by July 2021. On Dec. 18., the F.D.A. On Nov. 9, New York-based Pfizer and the German company BioNTech made history by presenting preliminary data indicating that their coronavirus vaccine was over 90 percent effective. The Indian company Biological E licensed it in August and launched a Phase 1/2 trial in November, combining the viral proteins with an adjuvant made by Dynavax. These trials further test the vaccine’s safety. On Sept. 11 they registered a Phase 1 trial in Taiwan. Injections began on Dec. 8, with William Shakespeare, age 81, among the first to receive a dose. When an executive with the company was later asked about the difference between the U.A.E. Before the pandemic, the Pennsylvania-based company Inovio developed DNA-based vaccines that are delivered into the skin with electric pulses from a hand-held device. PHASE 2 PHASE 3 COMBINED PHASES The researchers commenced a Phase 3 trial, anticipating approval by March.Updated Dec. 27, PHASE 1 PHASE 2 COMBINED PHASES On Dec. 22, the company announced a partnership with Pennsylvania-based Ocugen to develop Covaxin for the United States market.On Jan. 3, the Indian government granted Covaxin emergency authorization. The trial is planned to take place in early 2021 in Ukraine.Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. It was the first time anyone had found such evidence. The government rapidly set up clinics across the country where anyone could receive the vaccine. The true toll of the pandemic in the U.S. On Dec. 21, Xinhua reported that China was building a factory to produce 120 million doses per year.Updated Dec. 22, PHASE 1 EMERGENCY USE IN INDIA gave emergency approval for Sinopharm’s vaccine to use on health care workers, and soon government officials and others were also receiving it. Profit from additional features by authenticating your Admin account. Vaccine name: NVX-CoV2373 Recently, they’ve tackled influenza and anthrax using this technology. Storage: Refrigerated If trials proceed as expected, researchers predict that at least one of their candidates will be ready by late 2021.Updated Jan. 12, PHASE 1 ? They then infect insect cells with the virus, causing them to make the molecule in huge amounts. The researchers have found that the Covid-19 vaccine produces antibodies in mice. Algeria, Bolivia, the Palestinian Authority, Paraguay, Serbia, Turkmenistan and Venezuela authorized the vaccine in January.For more details, see How Gamaleya’s Vaccine Works.Updated Jan. 19, PHASE 2 PHASE 3 COMBINED PHASES The Gamaleya Research Institute, part of Russia’s Ministry of Health, has created a vaccine with an efficacy rate of 91.4 percent, according to a Dec. 14 announcement.Gamaleya produced the vaccine, initially called Gam-Covid-Vac, from a combination of two adenoviruses called Ad5 and Ad26. EARLY USE IN RUSSIA A Phase 3 trial began in November, and as of Dec. 15, the Interfax News Agency reported that 1,438 volunteers had received the vaccine. At least 90 preclinical vaccines are under active investigation in animals. Storage: Stable in refrigerator Dose: 2 doses, 3 weeks apart COMBINED PHASES: One way to accelerate vaccine development is to combine phases. In the wake of that reporting, the Department of Justice began investigating the company, while a number of shareholder lawsuits were brought against Vaxart, its executives and its board.Updated Nov. 12, PHASE 1 Dose: 2 doses, 4 weeks apart PHASE 2 EXPANDED TRIALS: Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. On Aug. 26, the Vector Institute, a Russian biological research center, registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. The vaccine is called Abadala, named after a poem by the nineteenth-century poet José Marti.Updated Nov. 30, PHASE 1 In July a Phase 3 trial began in the United Arab Emirates in July, and in Morocco and Peru the following month.On Sept. 14, the U.A.E. They launched a Phase 1 trial at the end of November.Updated Dec. 2, PHASE 1 The small San Francisco company Vaxart specializes in developing oral vaccines. Then you can access your favorite statistics via the star in the header. Type: Muscle injection In September, Yin Weidong, the CEO of Sinovac, said the company planned on worldwide distribution of the vaccine in early 2021 — including the United States. The company developed it in collaboration with the National Institute of Infectious Diseases and Kyushu University. gave emergency use authorization for a vaccine made by the Boston-based company Moderna. Efficacy: Unknown Instead, they may have to test against one of the vaccines expected to receive emergency use authorization by then. Entos instead chose the gene for nucleocapsid, a protein that sits inside the virus’s membrane. On Dec. 18, the researchers announced a collaboration with Enesi Pharma to formulate a solid version of the vaccine that can be implanted in the skin without a needle.Updated Jan. 7, PHASE 2 In that same month, Chinese government gave CoronaVac an emergency approval for limited use. Interactive tools, including maps, epidemic curves and other charts and graphics, with downloadable data, allow users to track and explore the latest trends, numbers and statistics at global, regional and country levels. Updated Statistics, graphs, and data tables showing the total number of cases, cases per day, cases by country, cases outside of Hubei in China, recoveries and discharges, newly infected, active cases, outcome of closed cases: death rate vs. recovery rate for patients infected with the COVID-19 Coronavirus originating from Wuhan, China Type: Muscle injection facts. Type: Muscle injection A previous version of the tracker listed Canadian approval of the Pfizer-BioNTech and Moderna vaccines, when in fact they were conditional authorizations. On Jan. 6 Arcturus announced that they had permission to start the Phase 2 portion of the trial in both Singapore and the United States. The elderly also showed the same efficacy rate as people under 65. Meanwhile, the trial has continued to gather data. On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. Other repurposed vaccines are in clinical trials being conducted by: the Bandim Health Project; Crown Coronation (Washington University and partner universities); Hôpitaux de Paris; Louisiana State University Health Sciences Center New Orleans; the BADAS Study (Texas A&M University, Baylor College of Medicine, M.D. The United States government bankrolled Moderna’s efforts, providing nearly $1 billion in support. Despite these questions, the United Kingdom and Argentina gave the vaccine emergency authorization on Dec. 30. Coronavirus (COVID-19) deaths worldwide per one million population as of January 20, 2021, by country [Graph]. Vaccine name: CoVLP Type: Muscle injection Cahill-Keyes map projection by Gene Keyes. Some of the proteins, from hepatitis B viruses, assemble themselves into hollow shells. Taiwan-based vaccine maker Medigen is making a vaccine made of a combination of spike proteins and an adjuvant from Dynavax. The vaccine contains genetic instructions for building a coronavirus protein, known as spike. In September, Dr. Albert Bourla, the chief executive of Pfizer, said the Phase 3 trial would deliver enough results as soon as October to show if the vaccine worked or not. This article provides a general overview and documents the status of locations affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes coronavirus disease 2019 (COVID-19) and is responsible for the COVID-19 pandemic.The first human cases of COVID-19 were identified in Wuhan, the capital of the province of Hubei in China in December 2019. After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Due to delays in funding and manufacturing, the trial is expected to begin in spring 2021. At the start of the pandemic, Inovio developed a DNA vaccine against the spike protein on the coronavirus. The neighboring country of Bahrain, which also participated in the Sinopharm trials, also gave full approval to the vaccine on Dec. 13. Efficacy: Unknown President Trump touted their progress, hinting that a vaccine would be available before the election. RIO DE JANEIRO (Reuters) - Brazil’s Health Ministry reported new COVID-19 statistics on Thursday showing the country fast approaching 1 million … They began Phase 1/2 trials on June 15 and have partnered with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health. Out of the 78 cases of Covid-19 in the trial, 20 were severe — and all 20 were in volunteers who received the placebo. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. Less than two months later, on Dec. 9, the U.A.E. After a series of promising experiments on animals, they began injecting volunteers for a Phase 1 trial in early October. Shafa Pharmed Pars, an Iranian pharmaceutical company, developed a vaccine made of inactivated coronaviruses. gave full approval to BBIBP-CorV, announcing it had an efficacy rate of 86 percent. Earlier studies on monkeys reportedly showed protective effects, and in the Phase 1 trial indicated it was safe in people. On Dec. 22, the company registered a Phase 1 clinical trial for adults.Updated Dec. 22, PRECLINICAL A Phase 2 trial followed on 750 volunteers, which led the researchers to select a two-week spacing between the two doses of the vaccine. On Nov. 9, the company announced that an interim analysis of the trial showed that the vaccine produced an immune response that’s in the range of responses seen in people who recovered from Covid-19. Some viral vector vaccines enter cells and cause them to make viral proteins. Vaccine name: COVAC The chairman and C.E.O. But worry that the vaccine was rushed to approval led to widespread hesitancy in the country. In March, the scientists were the first to put a Covid-19 vaccine into human trials. Unlike other leading vaccines in clinical trials, the company gave one dose, not two.Johnson & Johnson launched a Phase 3 trial in September. On June 30, the Japanese biotechnology company AnGes launched a Phase 1 trial to test a DNA-based vaccine, developed in partnership with Osaka University and Takara Bio. Sinovac published the details of the trial in November in a medical journal, showing a comparatively modest production of antibodies. Researchers at City of Hope, a California biomedical research institute, created a vaccine based on a weakened form of a virus called Modified Vaccinia Ankara, or MVA for short. The Serum Institute of India, which licensed the technology from SpyBiotech, is running the trials.Updated Sept. 24, PHASE 1 PHASE 2 COMBINED PHASES By Carl Zimmer, Jonathan Corum and Sui-Lee WeeUpdated Jan. 19, 2021. Mice don’t suffer symptoms of Covid-19, however, so the researchers then switched to hamsters, which do. Shionogi, a Japanese pharmaceutical giant, launched a Phase 1/2 trial of a coronavirus vaccine on Dec. 16. Brazil’s coronavirus stats can no longer be trusted, as the country moved to hide its total number of COVID-19 cases. In addition, the researchers announced that they found no serious side effects from the vaccine. The total number of cases and deaths registered country-wise is updated regularly. On Dec. 16, BioNTech announced a deal to supply China with 100 million doses. In January Cuba reached an agreement with Iran to test their vaccines.Updated Jan. 12, PHASE 2 Just over a month later, on Dec. 11, the Food and Drug Administration granted it the first emergency use authorization ever given by the United States to a coronavirus vaccine.BioNTech researchers began designing the vaccine, which now has the generic name tozinameran and the brand name Comirnaty, in January. estimate and Sinopharm’s own analysis, he said that both were “real and valid.” The difference was the result of differences in how the trials were run. Indonesia gave CoronaVac emergency authorization on Jan. 11, and two days later the president of Indonesia received an injection of CoronaVac on live television. If its clinical trials succeed, Novavax expects to deliver 100 million doses for use in the United States in 2021. On Oct. 14, Vladimir Putin announced that Russia has granted regulatory approval to the vaccine, making it the second one to receive that designation after the Gamaleya Institute’s Sputnik V vaccine. Brazil Coronavirus update with statistics and graphs: total and new cases, deaths per day, mortality and recovery rates, current active cases, recoveries, trends and timeline. So far, North Korea has not released any further information about the trials they supposedly are running.Updated Dec. 2, ABANDONED Emergency use in Britain, India, other countries. Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles.